Video
Dr. Hobbs on the Updated NCCN Guidelines in CML
Author(s):
Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).
Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).
One of the most exciting shifts in the CML landscape has been the revisions to the NCCN guidelines, says Hobbs. The NCCN guidelines are widely followed by physicians both in the United States and internationally to help treat and manage patients.
In light of recent data supporting the discontinuation of tyrosine kinase inhibitors (TKI), the NCCN guidelines as well as the European Leukemia Net Guidelines have recognized these data. It is now incorporated into the guidelines for treating physicians to reference.
The updated guidelines were based on a variety of clinical trials, explains Hobbs. Some of these trials include the STIM trials, the TWISTER trial, and the DADI trial. These trials, in conjunction with other trials, show that it is safe to discontinue TKIs if done properly, states Hobbs.
